DEPO Key Stats
- DEPOMED INC Files SEC form 8-K, Submission of Matters to a Vote of Security Hold... May 20
- DEPOMED INC Financials May 17
- Socially Responsible Investing in Biotech and Pharmaceutical Companies: Expert P... May 16
- Depomed To Present At UBS Global Healthcare Conference PR Newswire May 16
- Special Dividend and Ongoing Cash Distribution May 14
- DepoMed CEO Buys 25K Shares and 4 Insider Trades to Note May 14
- Monday 5/13 Insider Buying Report: DEPO, LNBB May 13
- DepoMed (DEPO) Rises on Key Insider Buy Street Insider May 13
- Did These Stocks Miss or Beat Analyst Expectations? May 12
- The Gory Details on DepoMed's Double Miss May 9
DEPO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). DepoMed is up 9.79% over the last year vs S&P 500 Total Return up 28.68%, Lannett Company up 200.5%, and SciClone Pharmaceuticals down 20.02%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for DEPO
Pro Report PDF for DEPO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download DEPO Pro Report PDF
Pro Strategies Featuring DEPO
Did DepoMed make it into our Pro Portfolio Strategies?